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Objective: Major Depressive Disorder (MDD) is associated with cognitive impairment
in general, and Executive Functioning (EF) in particular, even in remitted phase of the
disorder, suggesting residual cognitive symptoms. The aim of the present study was to
investigate self-reported EF 1 year after the first episode of MDD and to explore this in
relation to depressive mood symptoms, remission and relapse.
Method: The study included data from 24 patients and 23 healthy control subjects 1
year after the patients’ initial first episode of MDD. All participants completed the Behavior
Rating Inventory of Executive Functioning-Adult version (BRIEF-A), a standardized
self-report measure of perceived EF in everyday life, measuring nine different EF. Total
index scores for metacognitive functions, behavior/emotional regulation functions and a
global EF score is also calculated.
Results: The patient group in total, independent of symptom status, reported
significantly lower EF in all indexes compared to the healthy controls 1 year after the
initial episode. However, higher depressive mood symptom load correlated with self-
reported difficulties in metacognitive functions and poor global EF scores. Regulatory
control of behavior and emotional responses did not show such strong association with
mood symptoms, but low self-report scores on this measure was associated with relapse
during the first year after the initial episode.
Conclusion: First-episode patients report significant lower executive functioning in
everyday life compared to individually matched healthy controls, 1 year after onset,
independent of symptom load. Residual cognitive symptoms seem to be evident and
associated with risk of relapse and should be targeted in treatment and prevention of
recurrence in MDD.
Keywords: depression, first episode, cognitive functioning, residual cognitive symptoms, behavior rating inventory
of executive function
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INTRODUCTION
Major depressive disorder (MDD) is the most prevalent mental
disorder (1), and is characterized by significant disability,
including reduced social and work ability, and poor quality of
life (2). An important challenge is the relapsing and recurrent
nature of MDD (3), and despite relatively high-quality medical
and therapeutic treatment options where most patients achieve
symptom relief and remission, a high proportion of MDD
patients suffer from a relapse of depressive symptoms and
recurrence of depressive episodes (4). Studies have found that
∼50% of patients experience a relapse within the first 2 years
after the initial episode (5). Furthermore, the vulnerability
and risk of relapse is enhanced for each episode experienced
(6). The factors contributing to the high relapse risk and
recurrent course in MDD are not fully understood. Although
residual depressive mood symptomatology is recognized to be a
significant factor contributing to general disability, relapse and
recurrence in MDD (7), longitudinal studies of MDD patients
clearly show that mood symptoms alone are unlikely to present
a sufficient target for interventions (8). Studies have shown
that neurocognitive functioning might be a key determinant
affecting this relationship (9–11) with authors stressing the
importance of recognizing cognitive impairments in clinical
practice to improve clinical interventions (12). Importantly,
studies find that disability and poorer quality of life are found
to persist for years despite symptom reduction and remission
(13, 14), and cognitive impairment has been found to be
a significant illness characteristic mediating the association
between MDD and disability in everyday life (15, 16). One
study found that cognitive impairment in first episode patients,
especially Executive Functioning (EF) impairment, predicted
symptom severity in follow-up, highlighting the importance of
interventions and treatment of cognitive deficits at an early
stage of illness (11). Neurocognitive impairment in first episode
patients has also been associated with risk of relapse (5).
Research over the past two decades has documented
neurocognitive impairment to be a core feature of MDD and
characteristic of patient groups across the symptomatic phases
(10, 17–19). Findings have revealed impairment in several
cognitive domains such as processing speed, memory, attention
and EF (18). Importantly, although cognitive improvement
parallel to symptom recovery from the depressive episode has
been reported (20), several studies find cognitive impairment,
and especially EF impairment, to persist despite symptom
reduction and remission (9, 18, 21, 22). Longitudinal studies
following patients from the acute phase of illness through
phases of symptom reduction and remission have found that
impairment in psychomotor speed and memory often normalize
more in step with symptom reduction and remission, while
impairment of attention and especially EF persist beyond
remission, representing a prolonged neurocognitive impairment
despite symptom relief (22). Importantly, this pattern of
prolonged EF impairment has also been found in longitudinal
studies following first episode MDD patients (5, 23), showing
that these deficits are already present early in the course of the
illness and independent of depressive illness course. It has been
suggested that prolonged EF impairments represent stable traits
in MDD, which are possibly present before the first depressive
episode is even experienced (24). Thus, EF is recognized as
an important cognitive function to target in MDD. However,
EF is a broad, multi-functional concept, making it challenging
to investigate. EF is commonly defined as a set of cognitive
control processes that consist of several functions important for
governing behavior, including emotional regulation, the ability to
perform complex activities such as planning, organizing, and the
ability to sustain attention and self-management (25, 26). When
studying EF separately, a majority of studies find the EF functions
of inhibition and mental flexibility to be of importance in MDD.
In particular, the function of inhibition has been recognized
as a core EF function (27, 28), representing a function that is
common tomost EF functions, such asmental flexibility, working
memory, planning and problem solving, initiating and emotional
regulation. Poor EF in general, and poor inhibition in particular,
has been associated with lower treatment response (29), and to
represent a risk of relapse (5). Furthermore, poor EF has been
associated with poor rumination (30, 31) and poor emotional
regulation (32, 33).
Thus, when poor EF persists during phases of symptom
reduction and remission it represents an important residual
symptom affecting an individual’s recovery following depressive
episodes (5, 8, 34). EF is therefore suggested to be a core target in
the development of new treatment strategies for MDD (35, 36).
Research on neurocognitive functions in MDD is, however,
mostly based on studies using objective neuropsychological
tests or experimental designs. There are few empirical studies
investigating MDD patients’ subjective experience of cognitive
difficulties, and how this affects everyday life. Knowledge of
this is important due to the low correlation between objective
and subjective measures (37, 38) and the indication of low
ecological validity of objective test measures (39). Objective
neuropsychological tests in general have been found to have low
ecological validity in predicting everyday functioning (40). The
lack of ecological validity is especially prominent in measures
of EF performance (39, 41). Toplak et al. (39) argue that
objective test measurements only reveal few or specific EF
impairments; this is in contrast to self-reported measures, which
expose more severe and general impairments in everyday life.
Furthermore, subjective reported cognitive impairments inMDD
have been found to correlate more with socio-occupational
functioning than objective ratings (37). Thus, subjective reports
and descriptions may aid clinicians to better understand the
impact neurocognitive dysfunctions have in everyday life, and to
target more precise treatment interventions.
Studies addressing self-reported cognitive impairment in
general (using interviews, questionnaires and check lists) have
yielded important knowledge showing cognitive impairment
both during phases of depression and remission (7, 17, 37, 38).
One qualitative study found neurocognitive symptoms, such as
inability to concentrate, poor EF, memory, planning and problem
solving, and poor organization to be frequently reported by
patients with MDD and were described by patients to largely
affect their everyday functioning leading to low coping and
self-esteem (42). A matter of importance when investigating
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subjective self-reporting of cognition inMDD is to control for the
impact of depressive mood symptoms. Severity of illness, illness
chronicity, and younger age have been found to be positively
correlated with higher self-reported impairments (17), with
one study also showing that subjectively experienced cognitive
impairment was predicted by depression severity (38). Specific
for the assessment of self-reported EF using BRIEF-A, one study
reported a positive correlation between severity in symptom
load and self-reported impairment across diagnostic groups
(43). Thus, when investigating self-reported cognitive function,
one should correlate these reports to severity of depressive
mood symptoms.
Another important issue when investigating self-reported EF
impairment is the use of rating scales. Studies are divergent
with regard to the subjective ratings used. Some studies have
used traditional symptom scales or psychiatric interviews tapping
questions with cognitive content (7) while others have used
more detailed questionnaires tapping several cognitive functions
(38), which might not be specific enough to target how EF
impairments affect behavior in everyday life. This emphasizes
the importance of more systematically assessing self-report
questionnaires that specifically target EF, in order to enhance
the ecological validity of EF impairment. There is also a lack
of studies that have systematically investigated self-reported EF
impairment in MDD in a standardized manner.
The aim of the present study was therefore to investigate
self-reported EF in MDD 1 year after the initial episode of
MDD and to explore this in relation to mood symptoms,
remission and relapse. The standardized questionnaire developed
to assess EF in everyday life, The Behavior Rating Inventory of
Executive Function-Adult Version (BRIEF-A) [(44); Norwegian
translation (45)] was administered. The present study is part
of a comprehensive longitudinal project following a group of
first episode MDD patients for 1 year, investigating EF using
objective neuropsychological tests, and measuring patients in
both the acute phase of illness and after 1 year when the
patient group was in remission. Results revealed persistent EF
impairment in objective EF tests despite symptom reduction
and remission [for detailed descriptions see (5, 46)]. In the 1
year follow-up assessment, the study included subjective self-
report measures to enhance our understanding of EF following
initial episode.
Objectives and research questions
1. Do first-episode MDD patients report significantly lower EF
compared to healthy controls 1 year after the initial episode?
2. Are self-reported difficulties in EF associated with depressive
symptom load 1 year after the initial episode?
3. Are self-reported difficulties in EF related to relapse during
the first year after the initial episode?
Based on the previous literature, we expected the patient
group, independent of symptom load or remission, to
report significantly lower EF compared to the control group.
Furthermore, for the patient group, we expected that poorer EF
functions would be associated with symptom load and relapse
during the first year after initial episode.
MATERIALS AND METHODS
Study Subjects and Inclusion/Exclusion
Criteria
The study initially (T1) included 30 patients (16 males and
14 females) meeting the DSM-IV criteria for a unipolar
first episode MDD diagnosis using the MINI-International
Psychiatric Structural Interview (47). To assess the severity of
depression at both T1 and at the 1 year follow-up (T2), the
structural rating scale Montgomery Åsberg Depression Rating
Scale (MADRS) (48) was administered.
At T1, prospective patients were identified through
cooperation with doctors and psychologists in primary
healthcare, and the study coordinators were contacted if
patients met the inclusion criteria and agreed to be contacted by
the study coordinators for inclusion. Inclusion criteria for the
patient group at T1 were a diagnosis of first episode MDD and
a minimum score of 20 on the MADRS (indicating moderate
to severe depression). Patients diagnosed with, or receiving
treatment for, depression earlier in life; patients with known
brain injury, severe somatic disorders, or alcohol or substance
abuse; and patients who had been treated with electroconvulsive
therapy or who were psychotic or who had experienced psychosis
earlier in life, were excluded from the study.
At T1, a control group of 30 subjects was included who
were individually matched to the patient group with respect to
age, gender, and years of education (within a ± 2 year range).
Exclusion criteria for the control group were a history of brain
damage, any severe somatic disorder, any mental disorder, and
alcohol or substance abuse. Regarding the control group, all
participants were asked if they had a history of psychiatric
symptoms or diagnosis, and they were asked about depressive
symptoms at inclusion. To control for the effect of general
intellectual abilities (IQ), the two-subtest form of the Wechsler’s
Abbreviated Scales of Intelligence (WASI) (49) was administrated
at T1.
At both inclusion (T1) and the 1 year follow-up (T2), all
subjects were assessed according to demographic variables and
with a standardized neuropsychological test [for a more detailed
description, see (5, 46)]. All subjects were asked to participate
in the follow-up assessment 1 year later. One year follow-up
data from two patients were missing due to drop out. The study
coordinators were unable to contact one of these patients, and the
other did not want to participate in the follow-up assessment.
Dividing the Patient Group According to
Being in Remission and According to
Having had a Relapse Since Initial Episode
and the Use of Antidepressant Medication
At T2, patients were evaluated according to being in remission
and if they had experienced a relapse since inclusion. The
definition of a remission and relapse was based on suggested
operational criteria for outcomes in depression designed by
Frank et al. (50) and Rush et al. (51), and remission was also
defined according to suggested cut-off scores on MADRS (48)
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provided by Hawley et al. (52) and Rush et al. (51). At T2, patients
were divided according to depression severity into a Remitted
Group (RG) (N = 13) with MADRS score ≤ 9 and a Depressed
SymptomGroup (DSG) (N = 11) withMADRS score> 9 (which
indicates residual depressive symptoms). Furthermore, in order
to detect whether patients had experienced a relapse of their
depressive illness, all patients were interviewed retrospectively as
regards the course of their symptoms since inclusion and during
follow-up at T2. A drawn timeline from inclusion to follow-
up was used during the interview to obtain the most accurate
recall possible of the previous year’s events. A relapse was defined
as a return to a fully symptomatic state of depression after a
minimum 3 week period during which minimal symptom status
is maintained (remission). To fulfill the criteria of a relapse,
the subject had to report the relapse period as having lasted
a minimum of 2 weeks. In the present project a relapse was
further defined as a period during which the subject reported
difficulties performing at an optimal level in areas such as school,
work or social functioning. All patients were interviewed by
a psychologist. At T2, this categorization of patients resulted
in three different groups, where 11 patients had experienced a
relapse during the first year since the initial episode (Relapse
Group), 10 patients had not experienced a relapse (No Relapse
Group), and the remaining 3 patients had no change in symptom
load since inclusion. Patients were also divided according to the
use of antidepressant medication (N = 13) or not (N = 11) to
explore if this would influence the results.
BRIEF-A was administrated at T2, 1 year after inclusion.
Three patients and five control subjects did not complete or
deliver the BRIEF-A for various reasons. One patient was
identified as an outlier by the statistical programme due to
extreme and invalid BRIEF-A scores, and data from this patient
were removed from the analysis. Thus, BRIEF-A data from 24
patients and 23 control subjects were ultimately included, and
clinical and demographic data for the two groups are shown in
Table 1.
Procedure
Informed consent was obtained from all participants, and the
study was performed in accordance with theHelsinki Declaration
of the World Medical Association Assembly. The Regional
Committee forMedical Research Ethics and TheNorwegianData
Inspectorate approved the study.
Behavior Rating Inventory of Executive
Function-Adult Version (BRIEF-A)
Perceived EF in everyday life was measured using the BRIEF-A
self-report (44). The Norwegian translated version was used (45).
The BRIEF-A is a standardized self-report measure of executive
function in everyday life for adults aged 18 to 90 years. It consists
of 75 items reflecting behaviors to be rated as often a problem
(score 3), sometimes a problem (score 2), or never a problem
(score 1) in everyday life during the last months. Two summary
indexes are calculated—the Metacognition Index (MI) and the
Behavior Regulation Index (BRI). These summary indexes consist
of different EFs (44). TheMI is composed of the five clinical scales
Initiate, Working memory, Plan/organize, Task monitor and
TABLE 1 | Clinical and demographic variables for the patient and control groups
at T2.
Patients (n = 24) Controls (n = 23)
Variable M SD M SD t p
Age 27.38 5.63 27.43 5.09 −0.038 0.97ª
Male/Female 13/11 NA 13/10 NA NA NA
Education (years) 14.25 1.75 15.00 1.78 −1.46 0.153ª
Total IQ (WASI) 119.04 7.26 120.87 8.79 −0.779 0.440ª
MADRS T1 24.83 3.94 ** ** NA NA
MADRS T2 10.25 6.38 ** ** NA NA
**MADRS score is not reported for healthy controls. NA, not applicable.
ªIndependent samples t-test.
MADRS, Montgomery and Åsberg Depression Rating Scale; WASI: Wechsler Abbreviated
Scale of Intelligence.
Organization of Materials, and the BRI is composed of the four
clinical scales Inhibit, Shift, Emotional Control and Self-Monitor.
A Global Executive Composite (GEC) is calculated based on all
clinical EF scales (MI + BRI) to give a total EF score. Raw scores
are calculated for each clinical scale and for the summary indexes
(MI and BRI) and total score (GEC). The present study used raw
scores for the nine different scales and for the total MI, BRI, and
GEC scores. Raw scores are used in the main analysis because
no Norwegian norms for BRIEF-A are available. However, T-
scores (mean and standard deviations) are added in Table 4 for
clinical relevance. Studies that have included Norwegian norm-
samples have shown that this is a feasible and valid instrument
for use in Norway. However, these studies have also shown that
the clinical cut-off needs to be adjusted when interpreting the
result because the Norwegian norm-samples score ½ to 1 SD
below the original American norms (43, 53). The BRIEF-A also
includes the three validity scales of Negativity, Infrequency, and
Inconsistency. All BRIEF-A reports were evaluated with regard
to validity in accordance with the manual.
Data Scoring and Analyses
Independent sample t-tests were computed to compare the
patient and control group, and the two patient groups, as regards
age, years of education and IQ scores (see Tables 1, 2). A
one-way between-groups multivariate analysis of variance was
performed to compare the patient and control group on the
nine different BRIEF-A subscale raw scores and on the MI and
BRI indexes and the GEC. The dependent variables used were
BRIEF-A raw scores, and the independent variable was group
(patient or control). Higher scores reflected greater self-reported
impairment in EF. The relationship between BRIEF-A score
and severity of depression symptoms (measured by MADRS at
T1 and T2) were examined for the patient group by Pearson’s
correlation coefficient. To separate patients in remission from
patients with residual depressive symptoms, the patients were
divided according to depression severity measured with MADRS
into a Remitted Group (RG) and a group with residual depressive
symptoms, the Depressed Symptom Group (DSG). These groups
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TABLE 2 | Clinical and demographic variables for the Remitted Group (RG) (MADRS ≤ 9) and the Depressed Symptom Group (DSG) (MADRS > 9).
RG, MADRS ≤ 9 (N = 13) DSG, MADRS > 9 (N = 11)
Variable M SD M SD t pª
Age (years) 27.15 6.07 27.64 5.33 0.205 0.483
Male/Female 8/5 NA 5/6 NA NA NA
Education (years) 14.85 1.28 13.55 2.02 −1.92 0.068
MADRS* 5.46 2.18 15.91 4.74 6.72 <0.001
Total IQ (WASI) 118.54 8.24 119.64 6.23 0.362 0.721
ªIndependent samples t-test.
*MADRS: equal variances not assumed, statistics reported.
MADRS, Montgomery and Åsberg Depression Rating Scale; WASI, Wechsler Abbreviated Scale of Intelligence, NA, not applicable.
were compared to the Control Group (CG) on the main BRIEF-
A indexes using a between-groups multivariate analysis of
variance with post hoc analysis. Mean and Standard deviations
are provided for scores adjusted to American norms (T-score) for
clinical practical purposes. The patient group were also divided
according to the experience of relapse during the year since initial
episode using an independent samples T-test. An independent
samples T-test was also carried out to explore the difference
between patients that used medication and the patients that did
not regarding symptom severity (MADRS) and the EF indexes.
Preliminary assumption testing was conducted to check for any
statistical violations, and the data were examined for univariate
and multivariate outliers. One patient was identified as an outlier
by the statistical program due to extremely high scores, and data
from this patient were removed. When analyzing the data, the
assumption of homogeneity of variance was not met for the one-
way between-groups multivariate analysis of variance and the
post hoc analysis, thus the alpha level was interpreted with caution
and set to p < = 0.001.
RESULTS
The patient and control groups did not differ with regard to total
IQ, age or years of education. There was a relatively high standard
deviation for theMADRS score, in which raw scores ranged from
2 to 24 (see Table 1).
When dividing the groups by depression severity according
to MADRS, 13 patients had a score ≤ 9 and thus were in
remission, the Remitted Group (RG), and 11 patients had a score
> 9 indicating the presence residual mood symptoms or mild
to moderate depression, the Depressed Symptom Group (DSG).
The groups did not differ significantly with regard to total IQ, age,
or years of education (see Table 2).
BRIEF-A
There was a statistically significant difference between the patient
group and the control group on all clinical scales and combined
indexes on BRIEF-A. The main effect of group on the combined
dependent variables was statistically significant [F(9.37) = 9.09,
p < 0.001, Wilks’s lambda = 0.31, partial eta squared = 0.69].
When the clinical scales were analyzed separately, the patient
group reported significantly greater EF difficulties on all scales
(see Table 3 for raw scores, T-scores and statistics).
The BRIEF-A and Depression Severity
There were strong positive correlations between severity of
depression at T1 (MADRS) and self-reported EF impairment
(BRIEF-A) on the combined index MI (r = 0.498, N = 24, p
= 0.013), the BRI index (r = 0.530, N = 24, p = 0.008), and
GEC (r = 0.569, N = 24, p = 0.004), with higher severity of
depression at inclusion was associated with higher self-perceived
difficulties on all EF indexes. There were further a strong positive
correlations between severity of depression at T2 (MADRS) and
self-reported EF impairment (BRIEF-A) on the combined index
MI (r = 0.61, N = 24, p = 0.002) and GEC (r = 0.59, N =
24, p = 0.003), with higher severity of depression associated
with higher self-perceived difficulties on these EF indexes. There
were no significant correlations between depression severity
and the BRI index (r = 0.39, N = 24, p = 0.061). This
indicates that depression severity is strongly associated with
higher self-perceived impairment in metacognitive functions, but
that the association between depression severity and self-reported
regulatory control of behavior and emotional responses is not
that strong 1 year after initial episode.
Dividing the Patient Group by MADRS
Score
Dividing the patient group according to MADRS score revealed
significant differences between the three groups in self-reported
EF impairment, with patients in the Remitted Group (RG) (mean
MADRS score = 5.46, SD = 2.18, N = 13) and Depressed
Symptom Group (DSG) (mean MADRS score = 15.91, SD =
4.74, N = 11) self-reporting significantly greater impairment in
all EF in everyday life on the three main indexes (BRI Index, MI
index, GEC Index) compared to the Control Group (CG). The
results showed a statistically significant main effect of group on
the combined dependent variables [F(4, 86) = 15.67, p < 0.001,
Wilks’s lambda = 0.335, partial eta squared = 0.422]. Post hoc
comparisons using the Tukey HSD test showed that the control
group self-reported significantly lower EF difficulties in everyday
life compared to the two patient groups on all main indexes.
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TABLE 3 | BRIEF-A self-report for patient and control groups.
Patient group, N = 24 Control group, N = 23 Statistics
BRIEF-A M SD M SD F Sig. Eta Sq.
Inhibit 11.75 3.05 9.3 1.36 12.38 p < 0.001 0.22
Shift 9.83 2.79 6.78 1.17 23.51 p < 0.001 0.34
Emotional control 16.33 5.21 11.74 2.91 13.78 p < 0.001 0.23
Self-Monitor 7.87 1.82 6.48 0.79 11.41 p = 0.002 0.2
Beha.reg (BRI) 45.79 9.89 34.3 4.78 25.32 p < 0.001 0.36
Initiate 16.58 4.33 9.82 1.83 47.77 p < 0.001 0.52
Work memory 14.54 3.78 8.83 1.27 47.53 p < 0.001 0.51
Plan/Organize 18.13 4.56 11 1.2 52.54 p < 0.001 0.54
Task monitor 10.88 2.31 6.82 1.15 57.03 p < 0.001 0.56
Org. of materials 13.71 4.16 10.13 2.75 11.96 p = 0.001 0.21
Meta cog. (MI) 73.83 17.18 46.6 6.32 51.04 p < 0.001 0.53
EF Comp. (GEC) 119.63 24.27 80.91 10.12 50.11 p < 0.001 0.52
Mean (M), standard deviation (SD) and statistics (F, Sig., Eta Sq).
Analyses were carried out using raw scores.
Furthermore, post hoc tests also revealed that the DSG self-
reported significantly greater EF difficulties compared to the RG
group on all the main indexes.
Although the assumption of homogeneity of variance was not
met for these analyses, significance levels of<0.001 or 0.013 were
reached after correcting for unequal variances across groups (See
Table 4 for raw scores and statistics).
The Association Between Relapse During
the First Year After the Initial Episode and
Self-Reported EF
Dividing the patient group as regards experience of relapse
during the 1 year follow-up period revealed that the patients who
had experienced a relapse (N = 11, M = 9.09, SD = 5.18) did
not differ with regard to MADRS score at T2 compared to the
patients that did not have a relapse (N = 10,M= 8.60, SD= 5.82)
[t(19) = 0.205, p= 0.840]. However, the relapse group (N = 11, M
= 48.09, SD= 9.91) self-reported significantly more impairment
compared to the patients with no relapse experience (N = 10, M
= 40.40, SD= 5.15) on the BRI scale [t(15, 31) = 2.26, p= 0.039].
The magnitude of the difference in the means (mean difference=
7.69, 95% CI: 0.449 to 14.93) was large (Eta squared = 0.21). For
MI and total GEC, there were no significant differences between
the relapse group (MI: M= 72.0, SD= 16.79, GEC: M= 120.09,
SD = 25.31) and the no-relapse group (MI: M = 71.40, SD =
18.03, GEC: M= 111.80, SD= 19.40).
Dividing the Patient Group Concerning the
Use of Antidepressant Medication
Dividing the patient group according to those using
antidepressant medication (N = 13) and those that did not
(N = 11) showed that there was no difference in clinical
measures and self-reported EF difficulties. For the MADRS
score at T1 there were no difference between the ones that used
antidepressant medication (M = 25.38, SD = 4.53) and the ones
that did not (M = 24.18, SD = 3.19) [t(24) = 0.737, p = 0.469].
For MADRS score at T2 there were no difference between the
group that used medication (M = 11.23, SD = 6.53) and those
that did not (M = 9.09, SD = 6.27) [t(24) = 0.814, p = 0.424].
In the BRI Index there were no difference between patients that
used medication (M= 48.62, SD= 10.97) and the group that did
not (M = 42.45, SD = 10.97) [t(24) = 1.567, p = 0.131]. On the
MI index there were no difference between the group that used
medication (M = 76.31, SD = 19.12) and the patients that did
not (M = 70.91, SD = 14.94) [t(24) = 0.760, p = 0.456]. On the
GEC index there were no difference between the patients that
used medication (M = 124.92, SD = 27.13) and the patients that
did not (M= 13.36, SD= 19.80) [t(24) = 1.172, p= 0.254].
DISCUSSION
Themain aim of the present study was to investigate self-reported
EF 1 year after the first episode of MDD in relation to depressive
mood symptoms, remission and relapse. In addition, the impact
of clinical factors such as the use of medication was explored.
In order to broadly assess self-reported EF in everyday life, an
extensive and standardized questionnaire, BRIEF-A, was used.
Even though BRIEF-A is used frequently in clinical settings to
complement objective neuropsychological assessments (41), to
our knowledge there are only two studies using BRIEF- A in
MDD (54, 55). The former used BRIEF-A to assess effect of
cognitive training on patients and the latter was a pilot study with
no matched control group.
The results showed that 1 year after their initial episode,
first episode MDD patients reported significantly poorer EF
in everyday life compared to the healthy control group.
Furthermore, the present study found that depression severity
measured at inclusion, when patients were in the symptomatic
phase, and measured at 1 year after, were associated with self-
reported EF abilities at 1 year after initial episode. Symptom
load at initial episode was strongly associated with all EF
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TABLE 4 | Self-reported EF impairment for the Depressed Symptom Group (DSG); MADRS* > 9, Remitted Group (RG); MADRS* ≤ 9) and the Control Group (CG);
MADRS* N/A.
DSG, N = 11 RG, N = 13 CG, N = 23 Stat.
BRIEF-A raw scores M SD M SD M SD sig. post hoc
Beha.reg (BRI) 50.55 10.41 41.77 7.69 34.30 4.78 ** DSG<RG<CG
Metacog. (MI) 83.73 13.02 65.46 16.09 46.61 6.33 * DSG<RG<CG
EFComp. (GEC) 134.27 19.31 107.23 21.34 80.91 10.12 * DSG<RG<CG
BRIEF-A T-scores T SD T SD T SD
Beha.reg (BRI) 56.0 10.61 47.08 8.14 39.52 4.69 DSG<RG<CG
Metacog. (MI) 68.64 10.22 54.78 12.22 40.60 4.47 DSG<RG<CG
EFComp. (GEC) 64.45 9.33 51.62 10.15 39.21 4.53 DSG<RG<CG
Mean (M), standard deviation (SD), and statistics (Sig., post-hoc) for raw scores.
*T- scores (M) and (SD) are provided.
* sig < 0.001.
** sig = 0.013.
*T- scores based on American norms (44).
*MADRS, Montgomery Aasberg Depresssion Rating Scale.
index measures, which may indicate that those patients with
higher depressive symptom load at inclusion are the ones that
experience most difficulties in EF 1 year later. However, 1 year
after initial episode, these associations were only evident for some
EF abilities. Depressive mood symptoms correlated strongly with
reported EF difficulties in scales measuring metacognitive EF
(MI), such as Initiate, Plan/organize, Working memory and Task
monitor. There were no such strong association between mood
symptoms and self-reported difficulties on scales measuring
regulatory control of behavior and emotional responses (BRI),
such as Inhibition, Shift (mental flexibility), Emotional Control
and Self-Monitor. In order to further explore the impact of
depressive mood symptoms on self-experienced difficulties, the
patient group was divided according to being in remission
(defined asMADRS≤ 9) or not. Independent of group affiliation,
both patient groups reported significantly poorer EF compared to
the control group. This shows that difficulties in some EF abilities
are still evident despite remission. Moreover, the results showed
that patients who had experienced a relapse during the first initial
year reported significantly poorer EF in behavioral and emotional
regulatory (BRI) functions compared to the patients who did not
relapse, indicating that patients that have experienced relapse
report more difficulties in these EF abilities 1 year after initial
episode The use of antidepressant medication did not have any
impact on depressive symptom load at inclusion or 1 year after
initial episode or the self-reported EF indexes.
These results support previous findings of self-reported
cognition, or EF, being sensitive for depressive symptom load (17,
38, 43) but also support the hypothesis that EF impairment may
be independent of symptom severity, representing more stable
enduring residual cognitive symptoms affecting the individual
ability to regain former daily life functioning (5, 10, 18, 22).
These results may indicate that some EF difficulties, and
especially functions of inhibition, mental flexibility, emotional
regulation and self-monitor may be more stable traits making
the individual more vulnerable to relapse. However, the direction
of this relationship needs to be further investigated because
these patients might experience greater impairments because of
their relapse experience, making them more sensitive to own
emotional regulation.
The present study further finds a general poorer self-
report across several EF. This is in contrast to objective
measures which often finds specific EF to be impaired. This
may also be the reason that objective and subjective measures
seldom correlate. As argued by Toplak et al. (39), subjective
reports are more general, in that the patients often report a
more general and non-specific impairment which affects them
in most daily life activities. Toplak et al. (39) claim that
objective measures may address cognition at the core level of
neuropsychological functioning, while subjective measures of EF
may target situations of higher complexity, demanding more
general EF to solve complex behaviors in everyday life. Using
subjective ratings may add to our knowledge of how impairment
is experienced in everyday life. However, the present results
also to some extent mirror previous findings from objective
test measures with the indication that some EF, such as the
functions of inhibition, emotional regulation, mental flexibility
(shift), and self-monitor, may be of particular importance in
MDD, representing more stable impairments, less dependent on
depressive symptom severity, that possibly heighten the risk for
relapse. More specifically, the core EF functions of inhibition and
mental flexibility have been found to be important functions for
emotional regulation and regulatory control over behavior (30–
33). The finding that subjective measures also to some degree
identify these impairments to be more stable and independent of
symptom severity, adds support to previous studies arguing for
the importance of these residual symptoms when understanding
the illness course in MMD and targets for treatment.
Strengths and Limitations
A clear limitation in the present study is the small number
of participants and thereby low statistical power. Thus,
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generalization of the results should be made with caution and
results need to be replicated in larger samples. Nevertheless,
the significant results between groups despite low N should be
considered as robust and valid due to the minor risk of type I
error. Moreover, the patients represent a relatively homogenous
group, with higher IQ and years of education than average, which
also limits generalization and should be borne in mind when
interpreting the results. A strength is however that the patient
group was well-defined with regard to diagnostic criteria, as well
as symptom load, and the control group was matched for gender,
age and education. Further, the risk of conduction type II errors
has to be considered regarding border significant results.
Another limitation is that the BRIEF-A assessment was not
administrated at inclusion when patients were in the acute phase
of their illness; this could have added more information. For
example, it would have been possible to assess whether the
patient group’s self-reported EF changed during the course of
illness. Further, such data might have more precisely revealed the
direction of the relationship between self-reported impairment
and relapse, and knowing this wemight have been able to identify
the patients who are more vulnerable to relapse following their
initial episode. Further, although the present study finds that
patients in remission report difficulties in EF in everyday life,
one cannot exclude reporting bias due to depressive residual
symptoms. This is further limited due to the fact the control
group was only asked about symptoms and not screened for
depressive symptoms. By adding objective test measures and
statements from close relatives one could have controlled better
for this bias. Moreover, future studies should explore if clinical
characteristics can predict outcome of reported EF 1 year later.
Nevertheless, despite these limitations, the findings in the
present study add to our understanding of self-perceived
cognitive difficulties in EF 1 year after initial episode in First
Episode MDD patients. One strength of the present study is
the uniqueness of measuring self-reported EF 1 year after initial
episode and investigating the associations to depressive symptom
severity and relapse the previous year. To our knowledge, no
other study has conducted such a sampling. In addition, dividing
the patients as regards being in remission or not fortified
the study methodology, especially because the N was low and
thus more vulnerable to extreme scores. This approach thus
strengthens the finding that residual cognitive symptoms are
present even in remission.
An additional strength of the current study is the use of
a standardized, validated and reliable questionnaire of EF in
everyday life. Even though BRIEF-A is increasingly used in
clinical settings, to the best of our knowledge this is the first
empirical report using a control group in MDD in general and
in first-episode MDD in remission in particular.
Clinical Implications
The present findings showing that former depressed patients
experience neurocognitive difficulties in EF relative to healthy
control subjects, somewhat independent of depressive symptom
load, have several clinical implications. The results show that
there is an association between symptom severity and difficulties
in EF reported. However, importantly, despite being remitted,
difficulties with EF in everyday life is reported 1 year after initial
episode. Struggling with EF, such as initiating, planning and
organizing everyday life, having problems with workingmemory,
shifting of tasks and inhibiting negative thoughts along with
problems with emotional and behavioral regulation, will certainly
have a major impact in numerous arenas and settings. One can
imagine that family relations, social life and work capacity and/or
ability to study or go to school will be more challenging and thus
affected in a negative way. Moreover, not being able to meet the
domestic or work-related expectations from others or to achieve
and function according to one’s own expectations will potentially
lead to a feeling of not being able to cope with everyday life. This
could have a negative impact on self-esteem and thus potentially
increase the risk of relapse.
Targeted Interventions
The importance of identifying subjective experiences of poor
everyday EF in remission, and its association to symptom severity
and tendency to relapse, is most valuable in the treatment
and follow up of first episode MDD patients. The knowledge
regarding residual cognitive symptoms should guide clinical
evaluations and decisions made by healthcare personnel and
caregivers. In addition to traditional treatment that primarily
targets the emotional aspects of MDD, we should target
the cognitive aspects that manifest as residual symptoms in
MDD. Using BRIEF-A as primary measure, Hagen et al. (54)
showed improvement in self-reported EF depressive symptoms
after cognitive remediation treatment. Cognitive remediation
treatment is not the same as cognitive behavioral therapy, which
primarily targets cognitive thoughts. This treatment instead
targets cognitive functioning and aims to enhance cognitive
capacity in everyday life (8). Cognitive Enhancement Therapy
(CET) (8) seeks to improve cognitive and functional recovery and
is composed of three main components: (1) psychoeducation,
(3) practice, and (4) translation to everyday life. CET is still
in its infancy, and the patient group urgently needs us to
identify, acknowledge and more individually treat the residual
cognitive symptoms that apparently have such a major impact
on everyday life and represent a major risk for relapse. Self-
report measures need to be included when screening the
neuropsychological profile of the patient, in order to tailor the
intervention individually.
CONCLUSION
The present study showed that first-episode patients experienced
significant lower EF in everyday life compared to the control
group 1 year after onset. The lower EF were evident in both
patients in remission and in patients with depressive symptoms,
with most aspects of EF being associated depressive symptom
load, both initially and 1 year after the first episode. The findings
therefore indicate that EF difficulties may be affected by symptom
severity, but also that such difficulties may be present despite
being in remission. Further, the residual cognitive symptoms
of regulatory control of behavior and emotional responses was
associated with relapse. Poor EF should therefore be targeted
in future interventions in order to enhance our understanding
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of these difficulties, increase daily life functioning and prevent
relapses and/or new episodes.
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